ESMO Gastrointestinal Oncology

Association between neutropenia and efficacy in patients with refractory mCRC receiving trifluridine/tipiracil + bevacizumab: post hoc analysis of the SUNLIGHT trial

Pub Date : 2025-09-08 DOI: 10.1016/j.esmogo.2025.100234 G.W. Prager , E. Elez , M. Fakih , F. Ciardiello , E. Van Cutsem , L. Roby , W. Yao , E. Choucair , J. Taieb

An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX for HER2-low gastroesophageal adenocarcinoma

Pub Date : 2025-09-01 DOI: 10.1016/j.esmogo.2025.100207 Y. Aoki , I. Nakayama , Y. Komura , M. Wakabayashi , S. Fukuoka , H. Hara , H. Shoji , M. Furuta , K. Minashi , A. Sato , N. Fuse , N. Sakamoto , T. Kuwata , K. Shitara

Continuum of care and survival in patients with metastatic colorectal cancer: results of the real-world prospective, longitudinal cohort PROMETCO study

Pub Date : 2025-09-01 DOI: 10.1016/j.esmogo.2025.100214 M. Koopman , R. Garcia-Carbonero , C. Pinto , A. Mitroshkin , G. Bodoky , L. Mineur , V. Bourgeois , M. Mare , A. Ruiz-Casado , A. Fernandez Montes , J.M. O’Connor , A. Sullivan , E. Choucair , B. Chevallier , F. Marti Marti , J.-B. Bachet